Study to Evaluate Cellular Adoptive Immunotherapy Using Polyclonal Autologous CD8+ Antigen-Specific T Cells for Metastatic Merkel Cell Carcinoma in Combination With MHC Class I Up-Regulation and the Anti-PD-L1 Antibody Avelumab

Trial Profile

Study to Evaluate Cellular Adoptive Immunotherapy Using Polyclonal Autologous CD8+ Antigen-Specific T Cells for Metastatic Merkel Cell Carcinoma in Combination With MHC Class I Up-Regulation and the Anti-PD-L1 Antibody Avelumab

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Avelumab (Primary)
  • Indications Merkel cell carcinoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 06 Jun 2017 Results assessing the augmentation of adoptive T-cell therapy in patients from two related phase I/II trials (NCT01758458 and NCT02584829; n=8), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 01 Mar 2016 Time frame of primary endpoint (Incidence of adverse events) has been changed from upto 5 months after the last infusion to upto 12 months after last infusion and also treatment duration changed from 6 months to 12 months according to the ClinicalTrials.gov record.
    • 01 Mar 2016 Planned primary completion date changed from 1 Jan 2019 to 1 Jul 2019 according to the ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top